February 28, 2022
Life Sciences
  • Drugmaker Viatris Inc., formerly known as Mylan NV, will pay $264 million to settle a class-action lawsuit alleging it engaged in anticompetitive behavior to delay generic competition to its EpiPen allergy treatment. The litigation has been ongoing for years, following Mylan’s decision to hike EpiPen’s list price in 2008, though a U.S. district judge dismissed much of the case last year. (Article here)